The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids.

MAPK signaling pathways are constitutively active in colon cancer and also promote acquired resistance to MEK1 inhibition. Here, we demonstrate that BRAFV600E -mutated colorectal cancers acquire resistance to MEK1 inhibition by inducing expression of the scaffold protein CEMIP through a β-catenin- and FRA-1-dependent pathway. CEMIP was found in endosomes and bound MEK1 to sustain ERK1/2 activation in MEK1 inhibitor-resistant BRAFV600E-mutated colorectal cancers. The CEMIP-dependent pathway maintained c-Myc protein levels through ERK1/2 and provided metabolic advantage in resistant cells, potentially by sustaining amino acids synthesis. CEMIP silencing circumvented resistance to MEK1 inhibition, partly, through a decrease of both ERK1/2 signaling and c-Myc. Together, our data identify a cross-talk between Wnt and MAPK signaling cascades, which involves CEMIP. Activation of this pathway promotes survival by potentially regulating levels of specific amino acids via a Myc-associated cascade. Targeting this node may provide a promising avenue for treatment of colon cancers that have acquired resistance to targeted therapies.Significance: MEK1 inhibitor-resistant colorectal cancer relies on the scaffold and endosomal protein CEMIP to maintain ERK1/2 signaling and Myc-driven transcription. Cancer Res; 78(16); 4533-48. ©2018 AACR.

[1]  G. Evan,et al.  Myc Expression Drives Aberrant Lipid Metabolism in Lung Cancer. , 2016, Cancer research.

[2]  R. Bernards,et al.  Opportunities and challenges provided by crosstalk between signalling pathways in cancer , 2016, Oncogene.

[3]  Simon C Watkins,et al.  Endocytosis separates EGF receptors from endogenous fluorescently labeled HRas and diminishes receptor signaling to MAP kinases in endosomes , 2016, Proceedings of the National Academy of Sciences.

[4]  L. Wessels,et al.  Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival , 2015, Oncotarget.

[5]  Min Huang,et al.  c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. , 2015, Cancer research.

[6]  Jill S Barnholtz-Sloan,et al.  Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival , 2015, Oncotarget.

[7]  C. Atreya,et al.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Zhi-Yang Tsun,et al.  Amino acid management in cancer. , 2015, Seminars in cell & developmental biology.

[9]  M. Therrien,et al.  Regulation of RAF protein kinases in ERK signalling , 2015, Nature Reviews Molecular Cell Biology.

[10]  David S. Wishart,et al.  MetaboAnalyst 3.0—making metabolomics more meaningful , 2015, Nucleic Acids Res..

[11]  Nikhil Wagle,et al.  Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. , 2015, Cancer discovery.

[12]  Xudong Wang,et al.  Association between KIAA1199 overexpression and tumor invasion, TNM stage, and poor prognosis in colorectal cancer. , 2015, International journal of clinical and experimental pathology.

[13]  D. Sacks,et al.  IQGAPs choreograph cellular signaling from the membrane to the nucleus. , 2015, Trends in cell biology.

[14]  P. Delvenne,et al.  NF-κB-induced KIAA1199 promotes survival through EGFR signalling , 2014, Nature Communications.

[15]  Stein Aerts,et al.  iRegulon: From a Gene List to a Gene Regulatory Network Using Large Motif and Track Collections , 2014, PLoS Comput. Biol..

[16]  Andreas Schlicker,et al.  Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.

[17]  M. Kalady,et al.  BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta‐analysis , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[18]  A. Dufour,et al.  Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration. , 2013, Journal of the National Cancer Institute.

[19]  J. Locasale.  Serine, glycine and one-carbon units: cancer metabolism in full circle , 2013, Nature Reviews Cancer.

[20]  M. Meister,et al.  Mitogen-Activated Protein (MAP) Kinase Scaffolding Proteins: A Recount , 2013, International journal of molecular sciences.

[21]  Kun-Liang Guan,et al.  Nutrient sensing, metabolism, and cell growth control. , 2013, Molecular cell.

[22]  T. Qiu,et al.  Frequent Epigenetic Silencing of the Folate-Metabolising Gene Cystathionine-Beta-Synthase in Gastrointestinal Cancer , 2012, PloS one.

[23]  René Bernards,et al.  A Missing Link in Genotype-Directed Cancer Therapy , 2012, Cell.

[24]  Cem Kuscu,et al.  Transcriptional and Epigenetic Regulation of KIAA1199 Gene Expression in Human Breast Cancer , 2012, PloS one.

[25]  Wei Liu,et al.  Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC , 2012, Proceedings of the National Academy of Sciences.

[26]  Albert C. Koong,et al.  BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon: An Aggressive Adenocarcinoma With Poor Survival, Mucinous Differentiation, and Adverse Morphologic Features , 2012, The American journal of surgical pathology.

[27]  Sabine Tejpar,et al.  Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Versteeg,et al.  Mutations in the Ras–Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer , 2012, Clinical Cancer Research.

[29]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[30]  Hongying Shen,et al.  Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane , 2012, Proceedings of the National Academy of Sciences.

[31]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[32]  T. Ørntoft,et al.  Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells , 2011, British Journal of Cancer.

[33]  P. Edwards,et al.  Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.

[34]  A. Iafrate,et al.  BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation , 2010, Science Signaling.

[35]  C. Futter,et al.  Membrane contacts between endosomes and ER provide sites for PTP1B–epidermal growth factor receptor interaction , 2010, Nature Cell Biology.

[36]  Sabine Tejpar,et al.  Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.

[37]  Sun Young Park,et al.  Expression of cystathionine β-synthase is downregulated in hepatocellular carcinoma and associated with poor prognosis , 2009 .

[38]  K. Zeller,et al.  Global Regulation of Nucleotide Biosynthetic Genes by c-Myc , 2008, PloS one.

[39]  Fiona G. G. Nielsen,et al.  Genome-Wide Pattern of TCF7L2/TCF4 Chromatin Occupancy in Colorectal Cancer Cells , 2008, Molecular and Cellular Biology.

[40]  A. Smilde,et al.  How to distinguish healthy from diseased? Classification strategy for mass spectrometry‐based clinical proteomics , 2007, Proteomics.

[41]  H. Clevers,et al.  The Intestinal Wnt/TCF Signature. , 2007, Gastroenterology.

[42]  D. Sacks,et al.  IQGAP1 Is a Scaffold for Mitogen-Activated Protein Kinase Signaling , 2005, Molecular and Cellular Biology.

[43]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[44]  Ha-won Jeong,et al.  IQGAP1 Binds Rap1 and Modulates Its Activity* , 2004, Journal of Biological Chemistry.

[45]  D. Sacks,et al.  IQGAP1 Binds ERK2 and Modulates Its Activity* , 2004, Journal of Biological Chemistry.

[46]  C. Marshall,et al.  Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells , 2003, Journal of Cell Science.

[47]  D. Teis,et al.  Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. , 2002, Developmental cell.

[48]  E. Fauman,et al.  Identification of a Novel Mitogen-Activated Protein Kinase Kinase Activation Domain Recognized by the Inhibitor PD 184352 , 2002, Molecular and Cellular Biology.

[49]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[50]  Joyce Bos.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[51]  Sun Young Park,et al.  Expression of cystathionine beta-synthase is downregulated in hepatocellular carcinoma and associated with poor prognosis. , 2009, Oncology reports.

[52]  Z. Figaszewski,et al.  Altered membrane free unsaturated fatty acid composition in human colorectal cancer tissue , 2006, Molecular and Cellular Biochemistry.